XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
   Non-Hodgkin's Lymphoma
   Multiple Myeloma
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Multiple Myeloma Channel
subscribe to Multiple Myeloma newsletter

Latest Research : Cancer : Blood : Multiple Myeloma

   DISCUSS   |   EMAIL   |   PRINT
Lenalidomide & dexamethasone combination shows promise for multiple myeloma treatment
Sep 4, 2005, 07:16, Reviewed by: Dr.

"In this study, the first one to use the combination as initial therapy in newly diagnosed patients, we find that the Rev/Dex combination reduced the myeloma cancer protein levels by more than half in 91 percent of patients much higher than response rates obtained with current approved therapies."

 
Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (RevlimidTM) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.

"Previous studies have shown Rev/Dex to be effective for recurrent or highly resistant forms of myeloma," says S. Vincent Rajkumar, M.D., Mayo Clinic hematological oncologist and lead investigator of the study, "In this study, the first one to use the combination as initial therapy in newly diagnosed patients, we find that the Rev/Dex combination reduced the myeloma cancer protein levels by more than half in 91 percent of patients much higher than response rates obtained with current approved therapies."

The goal of this clinical trial was to determine the response rate and toxicity (type and severity of side effects) of Rev/Dex in patients with previously untreated, newly diagnosed multiple myeloma. Over the course of the trial, 34 patients underwent the combination treatment, with 31 (91 percent) showing positive response to the treatment, and all within a rapid period average response time was one month. In addition to the quick and positive responses, side effects were manageable, and common ones associated with thalidomide treatment, such as constipation, blood clots and neuropathy, were uncommon. Rev/Dex is administered orally making it a more attractive option to many patients compared to traditional intravenous treatments.

"We see this as potentially the way of the future for many myeloma patients," says Morie Gertz, M.D., Mayo hematological oncologist and co-investigator, "We are happy that two large Phase III trials are currently ongoing, moving forward the testing of Rev/Dex as initial therapy for myeloma."

Multiple myeloma is a malignant cancer of the blood that causes 11,000 deaths each year. Standard therapy of melphalan and prednisone results in about 50 percent of patients having a positive response i.e. the cancer cells lessen by more than half. Vincristine, doxorubicin and dexamethasone (VAD) is another chemotherapy regimen used to treat myeloma, typically for patients who are candidates for stem cell transplantation because it allows adequate and safe stem cell harvest during treatment for a future transplantation. However, the use of VAD chemotherapy has decreased greatly because of the need for intravenous therapy and the need for a catheter bringing other potential health risks.

Recent studies have looked at the oral combination of thalidomide and dexamethasone (Thal/Dex) as an alternative to VAD. Although response rates are excellent (approximately 70 percent), the combination causes significant side effects. Lenalidomide is a compound similar to thalidomide, but one which previous studies have shown to work better both for recurrent and highly resistant myelomas, both alone and in conjunction with dexamethasone. It has fewer side effects than thalidomide and has even caused improvement in patients who are nonresponsive to thalidomide.

Lenalidomide is not commercially available; approval by the Food and Drug Administration is pending. The study was funded with grants from the National Cancer Institute and Celgene Corporation, which manufactures RevlimidTM.
 

- Results of a Phase II clinical trial were published online Aug. 23 in Blood
 

Mayo Clinic

 
Subscribe to Multiple Myeloma Newsletter
E-mail Address:

 

For more information on clinical trials at Mayo Clinic, go to http://clinicaltrials.mayo.edu, and for more information on treatment of multiple myeloma, go to www.mayoclinic.org/multiple-myeloma.

Related Multiple Myeloma News

Lenalidomide & dexamethasone combination shows promise for multiple myeloma treatment
Novel combination overcomes drug-resistant myeloma
Bortezomib Based Therapies may Become the New Standard of Care in Multiple Myeloma
FDA Fully Approves Bortezomib for Treatment of Relapsed and Refractory Multiple Myeloma


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us